All Stories

  1. Win Ratio Analysis to Clarify Clinical Benefits: A Post Hoc Analysis of Phase 3 BOREAS and NOTUS

    Article • CHEST Journal, March 2026, Elsevier

    Dr Sanjay Ramakrishnan

  2. Monoclonal antibody therapy in COPD: will it prevent hospitalisations?

    Article • American Review of Respiratory Disease, February 2026, Oxford University Press (OUP)

    Dr Sanjay Ramakrishnan

  3. Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) model

    Article • The Lancet Respiratory Medicine, February 2026, Elsevier

    Dr Sanjay Ramakrishnan

  4. Blood Eosinophil Counts in Healthy Volunteers and in Patients with Asthma and COPD in India: A Multi-Centre Cross-Sectional Report

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2025, Taylor & Francis

    Dr Sanjay Ramakrishnan

  5. One Breath Wonder

    Article • CHEST Journal, December 2025, Elsevier

    Dr Sanjay Ramakrishnan

  6. Applying precision medicine to the heterogeneity of asthma attacks

    Article • CHEST Journal, November 2025, Elsevier

    Dr Sanjay Ramakrishnan

  7. Exhaled nitric oxide (FeNO) and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Rα therapy: a prospective observational study

    Article • European Respiratory Journal, October 2025, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  8. Win ratio analysis of dupilumab efficacy in patients with chronic obstructive pulmonary disease and type 2 inflammation: BOREAS and NOTUS

    Article • September 2025, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  9. Breathing barriers: bridging lung health, research, and awareness

    Article • The Lancet Respiratory Medicine, August 2025, Elsevier

    Dr Sanjay Ramakrishnan, Dr Lydia Finney

  10. In the Land of Asthma, 4 Risk Factors to Rule Them All

    Article • CHEST Journal, August 2025, Elsevier

    Dr Sanjay Ramakrishnan

  11. Type 2 inflammatory biomarkers in asthma and COPD: what we think we know

    Article • European Respiratory Journal, July 2025, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  12. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials

    Article • The Lancet Respiratory Medicine, June 2025, Elsevier

    Dr Sanjay Ramakrishnan

  13. Digitally mapping the asthma journey—from diagnosis to remission

    Article • EClinicalMedicine, May 2025, Elsevier

    Dr Sanjay Ramakrishnan

  14. Using an Eosinophil Count to Diagnose Asthma: Music to Your EARS?

    Article • Respirology, February 2025, Wiley

    Dr Sanjay Ramakrishnan

  15. Viewpoint: a white paper for a greener design, conduct and reporting of clinical trials in respiratory medicine

    Article • European Respiratory Journal, February 2025, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  16. Ensifentrine for COPD

    Article • CHEST Journal, February 2025, Elsevier

    Dr Sanjay Ramakrishnan

  17. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial

    Article • The Lancet Respiratory Medicine, January 2025, Elsevier

    Dr Sanjay Ramakrishnan

  18. P181 Bactericidal/ permeability-increasing protein is present in plasma of stable and exacerbating COPD patients

    Article • November 2024, BMJ

    Dr Sanjay Ramakrishnan

  19. S109 Treating eosinophilic exacerbations of asthma and COPD with benralizumab: a double blind, double dummy, active-placebo controlled randomised trial (ABRA)

    Article • November 2024, BMJ

    Dr Sanjay Ramakrishnan

  20. S63 Eosinophilic inflammation at exacerbations of COPD is associated with less dynamic troponin rises in the 30 days post exacerbation

    Article • November 2024, BMJ

    Dr Sanjay Ramakrishnan

  21. T6 Exhaled nitric oxide (FeNO) predicts clinical and anti-inflammatory response to prednisolone for breakthrough attacks in anti-IL5/IL5R treated asthma

    Article • November 2024, BMJ

    Dr Sanjay Ramakrishnan

  22. Watchful waiting in laryngo‐tracheobronchial amyloid: A case report

    Article • Respirology Case Reports, November 2024, Wiley

    Dr Sanjay Ramakrishnan

  23. Steroids in cystic fibrosis exacerbations: are we picking the right patients?

    Article • European Respiratory Journal, October 2024, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  24. RCT Abstract - Treating eosinophilic exacerbations of asthma and COPD with benralizumab: a double-blind, double-dummy, active-placebo randomised controlled trial (ABRA)

    Article • September 2024, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  25. The healing power of sensory neurons: New horizons for diabetic and neuropathic tissue repair

    Article • Clinical and Translational Medicine, August 2024, Wiley

    Dr Sanjay Ramakrishnan

  26. Blood eosinophils and lung function loss: from passive prediction to active prevention?

    Article • European Respiratory Journal, May 2024, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  27. Multiple Event-time Analysis: A New Approach for Event Based Clinical Trials in Obstructive Airway Diseases

    Article • April 2024, American Thoracic Society

    Dr Sanjay Ramakrishnan

  28. Predicting Severe Asthma Attacks With Blood Eosinophils and Exhaled Nitric Oxide (FeNO): Initial Data Analysis for the ORACLE Patient-level Meta-analysis

    Article • April 2024, American Thoracic Society

    Dr Sanjay Ramakrishnan

  29. The Exacerbation, Not the Patient, Determines Chronic Obstructive Pulmonary Disease Exacerbation Care Seeking

    Article • Annals of the American Thoracic Society, April 2024, American Thoracic Society

    Dr Sanjay Ramakrishnan

  30. Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19

    Article • ERJ Open Research, February 2024, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  31. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial

    Article • The Lancet Respiratory Medicine, January 2024, Elsevier

    Dr Sanjay Ramakrishnan

  32. Trailblazing Clinical Trials in Asthma, COPD, Sleep Medicine, and Education and Clinical Practice in 2023

    Article • CHEST Journal, January 2024, Elsevier

    Dr Sanjay Ramakrishnan

  33. How have we measured trial outcomes of asthma attack treatment? A systematic review

    Article • ERJ Open Research, December 2023, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  34. Building healthcare professionals consensus on non-pharmacological patient care priorities during hospitalisation and post-discharge phases following acute exacerbation of chronic obstructive pulmonary disease (AECOPD)

    Article • September 2023, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  35. Nodal analysis determined nasal mucosal-associated mediators were associated with accelerated clinical recovery from SARS-CoV-2 infection

    Article • September 2023, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  36. Prednisolone for COPD exacerbations: time for a rethink

    Article • ERJ Open Research, September 2023, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  37. Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)

    Article • JMIR Research Protocols, June 2023, JMIR Publications Inc.

    Dr Sanjay Ramakrishnan

  38. Patients’ acceptance of outcome and experience measurements during hospitalisation for COPD exacerbations: a CICERO Clinical Research Collaboration–European Lung Foundation online patient survey

    Article • ERJ Open Research, May 2023, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  39. Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST) (Preprint)

    Article • March 2023, JMIR Publications Inc.

    Dr Sanjay Ramakrishnan

  40. Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19

    Article • March 2023, Springer Science + Business Media

    Dr Sanjay Ramakrishnan

  41. Chronic obstructive pulmonary disease: 10 years of precision-guided success

    Article • The Lancet Respiratory Medicine, March 2023, Elsevier

    Dr Sanjay Ramakrishnan

  42. Maintenance Pulmonary Rehabilitation

    Article • CHEST Journal, December 2022, Elsevier

    Dr Sanjay Ramakrishnan

  43. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis

    Article • The Lancet Respiratory Medicine, June 2022, Elsevier

    Dr Sanjay Ramakrishnan

  44. Chronic Obstructive Pulmonary Disease Exacerbations: Do All Roads Lead to Rome?

    Article • American Review of Respiratory Disease, May 2022, American Thoracic Society

    Dr Sanjay Ramakrishnan

  45. Ethnicity-based differences in asthma diagnostic thresholds

    Article • The Journal of Allergy and Clinical Immunology In Practice, April 2022, Elsevier

    Dr Sanjay Ramakrishnan

  46. European Respiratory Society International Congress 2021: highlights from best-abstract awardees

    Article • Breathe, March 2022, European Respiratory Society (ERS)

    Joana Cruz, Dr Sanjay Ramakrishnan

  47. Heterogeneity of IPF exacerbations

    Article • The Lancet Respiratory Medicine, January 2022, Elsevier

    Dr Sanjay Ramakrishnan

  48. Biomarkers in COPD

    Article • January 2022, Elsevier

    Dr Sanjay Ramakrishnan

  49. Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

    Article • October 2021, Cold Spring Harbor Laboratory Press

    Dr Sanjay Ramakrishnan

  50. Patient perspective of participation in COVID-19 clinical trials

    Article • September 2021, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  51. Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

    Article • September 2021, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  52. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

    Article • The Lancet, September 2021, Elsevier

    Dr Sanjay Ramakrishnan

  53. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide

    Article • Thorax, August 2021, BMJ

    Dr Sanjay Ramakrishnan

  54. Eosinophilic inflammation, coronavirus disease 2019, and asthma

    Article • Annals of Allergy Asthma & Immunology, August 2021, Elsevier

    Dr Sanjay Ramakrishnan

  55. Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review

    Article • BMJ evidence-based medicine, July 2021, BMJ

    Dr Sanjay Ramakrishnan

  56. Antibiotics for asthma attacks: masking uncertainty

    Article • European Respiratory Journal, July 2021, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  57. Inhaled budesonide for early treatment of COVID-19 – Authors' reply

    Article • The Lancet Respiratory Medicine, July 2021, Elsevier

    Dr Sanjay Ramakrishnan

  58. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

    Article • The Lancet Respiratory Medicine, July 2021, Elsevier

    Dr Sanjay Ramakrishnan

  59. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma

    Article • Cochrane Database of Systematic Reviews, May 2021, Wiley

    Hebatullah Abdulazeem, Dr Sanjay Ramakrishnan

  60. A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)

    Article • May 2021, American Thoracic Society

    Dr Sanjay Ramakrishnan

  61. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial

    Article • April 2021, Cold Spring Harbor Laboratory Press

    Dr Sanjay Ramakrishnan

  62. Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

    Article • February 2021, Cold Spring Harbor Laboratory Press

    Dr Sanjay Ramakrishnan

  63. Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2021, Taylor & Francis

    Dr Sanjay Ramakrishnan

  64. P144 Standardising follow up of symptoms, tests, and outcome assessment after hospitalisation for exacerbation of COPD – A Delphi Survey

    Article • January 2021, BMJ

    Dr Sanjay Ramakrishnan

  65. Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled Trial

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Dr Sanjay Ramakrishnan

  66. Reply to Lipworth et al.: Don’t Forget about Facilitatory Effects of Corticosteroids on β2-Adrenoceptors in Acute Asthma

    Article • American Review of Respiratory Disease, December 2020, American Thoracic Society

    Dr Sanjay Ramakrishnan

  67. Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma

    Article • American Review of Respiratory Disease, November 2020, American Thoracic Society

    Dr Sanjay Ramakrishnan

  68. Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

    Article • September 2020, European Respiratory Society (ERS)

    Angela Moran, Dr Sanjay Ramakrishnan

  69. European expert consensus on assessment and management of hospitalised exacerbations of COPD (CICERO ERS CRC)

    Article • September 2020, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  70. The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach

    Article • American Review of Respiratory Disease, June 2020, American Thoracic Society

    Dr Sanjay Ramakrishnan

  71. Chronic obstructive pulmonary disease: management of chronic disease

    Article • Medicine, May 2020, Elsevier

    Dr Sanjay Ramakrishnan

  72. The CICERO (Collaboration In COPD ExaceRbatiOns) Clinical Research Collaboration

    Article • European Respiratory Journal, March 2020, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  73. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma

    Article • Cochrane Database of Systematic Reviews, January 2020, Wiley

    Dr Sanjay Ramakrishnan

  74. Is it time to give up on “self-management” of COPD exacerbations?

    Article • European Respiratory Journal, January 2020, European Respiratory Society (ERS)

    Dr Sanjay Ramakrishnan

  75. In the race at last: post-hoc analysis of GALATHEA and TERRANOVA

    Article • The Lancet Respiratory Medicine, September 2019, Elsevier

    Dr Sanjay Ramakrishnan